Get to know our clinical trials
Clinical trial of sacituzumab timurotecan (sac-TMT, MK-2870) as maintenance therapy in participants with advanced ovarian cancer
THE PRIMARY OBJECTIVE IS TO COMPARE SAC-TMT MAINTENANCE THERAPY WITH OR WITHOUT BEVACIZUMAB AGAINST STANDARD OF CARE (SOC) IN TERMS OF PFS AS DEFINED BY RECIST 1.1, AS ASSESSED BY THE BICR.
Technical Summary
- A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 STUDY OF SACITUZUMAB TIMUROTECAN (SAC-TMT, MK-2870) AS MAINTENANCE THERAPY, WITH OR WITHOUT BEVACIZUMAB, COMPARED WITH STANDARD OF CARE IN PARTICIPANTS WITH NEWLY DIAGNOSED HRD-NEGATIVE ADVANCED OVARIAN CANCER WHO HAVE RECEIVED FIRST-LINE PLATINUM-BASED CHEMOTHERAPY (TROFUSE-021/ENGOTOV85/GOG-3102)
- Code EudraCT: 2023-508047-40
- Protocol number: MK-2870-021
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: sacituzumab timurotecán (sac-TMT, MK-2870)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.